Arbovax Closing in on Vaccine for Chikungunya

Arbovax, Inc., a clinical stage biotechnology company, has successfully demonstrated in an animal model the efficacy of its vaccine technology for the treatment of Chikungunya, a mosquito borne virus that has recently emerged in the US. “There was a major outbreak in the Caribbean that... - June 21, 2014

Arbovax Completes Successful Pre-Clinical Trial of Tetravalent Dengue Vaccine

Successful Pre-Clinical Tests Support Vaccine Platform, New Injection Protocol - March 19, 2013

New Virus Modification Approach to Creating Vaccines for Insect-Borne Diseases

A technology breakthrough that could have a major impact in the development of vaccines to preventive insect-borne diseases has been published in the June edition of Virology Journal, - July 07, 2011

One-Shot Dengue Fever Vaccine Moves Closer to Reality

Arbovax, Inc. is an early stage biotechnology company based in Raleigh NC, developing a novel and innovative technology to facilitate the development of vaccines against insect-borne viruses. Their initial focus, Dengue Fever, is ranked second only to Malaria by the World Health Organization for its devastating global impact. - June 21, 2011

Press Releases 1 - 4 of 4